Follow The Filings

ADMA Adma Biologics Inc.

Health Care, filed as ADMA BIOLOGICS INC (COM), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

Bought by 1 manager in 2026 Q2

  • 2 Owners
  • Max 0.5%
  • $37M
  • 1 add

In 2026 Q2 Stanley Druckenmiller added to Adma Biologics.

Who owns this now

Largest portfolio weights among holders, up to 0.5% (Stanley Druckenmiller, Duquesne Family Office). Not free-float ownership.

  1. Stanley Druckenmiller Add 0.45%
  2. Terry Smith 0.10%

Who owns ADMA

Sorted by value, long equity only, as of 2026 Q2.

History
Stanley Druckenmiller, Duquesne Family Office 0.45%, was 0.42% Add +80.1% 2,784,110 $23M History
Terry Smith, Fundsmith 0.10% Hold 1,649,493 $14M History

2 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by ADMA's executives, directors and 10% owners in the last 12 months, from their Form 4s

All ADMA insider trades
  • $468K bought by 2 insiders
  • $158K sold by 1 insider outside a trading plan
  • $3.2M sold by 1 insider under 10b5-1 plans
  1. Adam S Grossman CEO
    Planned sale
    $1.8M 147,000 shares at $12.00 6.6% of stake
    Traded Nov 5 Filed Nov 5
    ↗
  2. Jerrold B Grossman Director
    Buy
    $51K 6,400 shares at $7.91 +1.2% to stake
    Traded May 27 Filed May 28
    ↗
  3. Jerrold B Grossman Director
    Buy
    $100K 12,500 shares at $8.01 +2.5% to stake
    Traded May 12 Filed May 14
    ↗
  4. Jerrold B Grossman Director
    Buy
    $100K 12,500 shares at $8.01 +2.6% to stake
    Traded May 11 Filed May 12
    ↗
  5. Adam S Grossman CEO
    Planned sale
    $318K 21,000 shares at $15.16 1% of stake
    Traded Mar 16 Filed Mar 17
    ↗
  6. Kaitlin M. Kestenberg-Messina COO
    Sale
    $158K 10,096 shares at $15.63 2.1% of stake
    Traded Mar 9 Filed Mar 10
    ↗
  7. Steve Elms Director
    Buy
    $217K 14,000 shares at $15.53 +0.7% to stake
    Traded Mar 5–6 Filed Mar 9
    ↗
  8. Adam S Grossman CEO
    Planned sale
    $338K 21,000 shares at $16.08 0.9% of stake
    Traded Feb 17 Filed Feb 17
    ↗
  9. Adam S Grossman CEO
    Planned sale
    $416K 21,000 shares at $19.79 1% of stake
    Traded Dec 15, 2025 Filed Dec 16, 2025
    ↗
  10. Adam S Grossman CEO
    Planned sale
    $336K 21,000 shares at $16.00 1% of stake
    Traded Nov 19, 2025 Filed Nov 21, 2025
    ↗
  11. Adam S Grossman CEO
    Planned sale
    $336K 21,000 shares at $16.00 1% of stake
    Traded Oct 24, 2025 Filed Oct 24, 2025
    ↗

Also filed in the last 12 months, not counted as buying or selling: 11 option exercises, 10 share withholdings for taxes, 9 stock grants, 2 gifts, and 1 other transaction.

SEC filings

Recent issuer filings from EDGAR, 18 shown.

Filed Form Detail Links
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
SCHEDULE 13G — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
8-K 5.07 Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
8-K 8.01,9.01 Filing Doc
SCHEDULE 13G — Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc
8-K 7.01,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 7.01,8.01,9.01 Filing Doc
8-K 2.02,5.02,9.01 Filing Doc
10-K Filing Doc
SCHEDULE 13G/A — Filing Doc

Source: SEC EDGAR submissions, updated about 8 hours ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $258.22M $426.45M $510.17M
Gross profit $88.94M $219.55M $292.76M
Gross margin * 34.4% 51.5% 57.4%
Net income -$28.24M $197.67M $146.93M
Net margin * -10.9% 46.4% 28.8%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $257.01M $331.41M $466.51M
Total non-current assets * $72.17M $157.27M $157.73M
Total assets $329.18M $488.68M $624.24M
Total current liabilities $49.81M $55.54M $69.54M
Total non-current liabilities * $144.17M $84.12M $77.38M
Total equity $135.21M $349.02M $477.32M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations $8.8M $118.67M $50.4M
Cash from investing -$4.98M -$8.58M -$21.89M
Cash from financing -$38.99M -$58.3M -$44.02M
Net change in cash -$35.17M $51.8M -$15.52M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.

Further reading

As an Amazon Associate, FollowTheFilings earns from qualifying purchases.

More on the shelf